

# Mara Chaparro

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6833719/maria-chaparro-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189  
papers

5,512  
citations

39  
h-index

67  
g-index

245  
ext. papers

6,868  
ext. citations

3.9  
avg, IF

5.88  
L-index

#	Paper	IF	Citations
189	Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 125-45	6.1	390
188	Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 847-58.e4; quiz e48-50	6.9	246
187	Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 1404-10	4.5	190
186	Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 613-23	6.1	184
185	Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 645-59	6.1	169
184	Safety of thiopurines and anti-TNF- $\alpha$ drugs during pregnancy in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 433-40	0.7	157
183	Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. <i>Gut</i> , <b>2010</b> , 59, 1340-6	19.2	136
182	Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 1662-9	4.5	113
181	Clinical patterns and outcomes of ischaemic colitis: results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE study). <i>Scandinavian Journal of Gastroenterology</i> , <b>2011</b> , 46, 236-46	2.4	108
180	Systematic review with meta-analysis: inflammatory bowel disease in the elderly. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 459-77	6.1	105
179	Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 2026-33	4.5	100
178	The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 632-47	0.7	99
177	Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1460-6	0.7	98
176	Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. <i>Gastrointestinal Endoscopy</i> , <b>2013</b> , 77, 381-389.e1	5.2	97
175	Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. <i>Journal of Clinical Gastroenterology</i> , <b>2011</b> , 45, 113-8	3	97
174	Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 1426-38	0.7	88
173	Microbiota Sensing by Mincle-Syk Axis in Dendritic Cells Regulates Interleukin-17 and -22 Production and Promotes Intestinal Barrier Integrity. <i>Immunity</i> , <b>2019</b> , 50, 446-461.e9	32.3	87

172	Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 619-33	6.1	87
171	Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 275-83	6.1	83
170	Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 340-8	6.1	76
169	Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 1430-1439	1.5	72
168	Systematic review: antibodies and anti-TNF- $\beta$ levels in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 971-86	6.1	72
167	Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 391-405	6.1	68
166	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 120-131	0.7	66
165	Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. <i>Journal of Crohn's and Colitis</i> , <b>2012</b> , 6, 518-23	1.5	65
164	Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 1379-85	6.1	62
163	Accuracy of computed tomographic colonography for the detection of polyps and colorectal tumors: a systematic review and meta-analysis. <i>Digestion</i> , <b>2009</b> , 80, 1-17	3.6	61
162	H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. <i>Gut</i> , <b>2011</b> , 60, 456-62	19.2	60
161	Human intestinal pro-inflammatory CD11cCCR2CX3CR1 macrophages, but not their tolerogenic CD11cCCR2CX3CR1 counterparts, are expanded in inflammatory bowel disease. <i>Mucosal Immunology</i> , <b>2018</b> , 11, 1114-1126	9.2	56
160	Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 894-901	4.5	55
159	Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 694-709	1.5	54
158	Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 839-851	6.1	53
157	Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 1269-77	6.1	51
156	Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1394-1402	4.5	47
155	Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy. <i>Journal of Clinical Gastroenterology</i> , <b>2015</b> , 49, 34-40	3	46

154	Should we monitor vitamin B12 and folate levels in Crohn's disease patients?. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 1272-7	2.4	45
153	Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn's disease: are antibiotics enough?. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 1509-14	4.5	44
152	Long-term durability of response to adalimumab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 685-90	4.5	43
151	Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1709-1718	0.7	42
150	Identification of risk loci for Crohn's disease phenotypes using a genome-wide association study. <i>Gastroenterology</i> , <b>2015</b> , 148, 794-805	13.3	39
149	Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. <i>Journal of Oncology</i> , <b>2010</b> , 2010, 272170	4.5	39
148	Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 11273-81	5.6	35
147	Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. <i>Journal of Gastroenterology</i> , <b>2017</b> , 52, 788-799	6.9	33
146	Intensification of infliximab therapy in Crohn's disease: efficacy and safety. <i>Journal of Crohn's and Colitis</i> , <b>2012</b> , 6, 62-7	1.5	32
145	Mechanisms of angiogenesis in chronic inflammatory liver disease. <i>Annals of Hepatology</i> , <b>2007</b> , 6, 208-213	3.1	32
144	Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. <i>Current Pharmaceutical Biotechnology</i> , <b>2011</b> , 12, 765-73	2.6	32
143	Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 481-490	4	31
142	Role of food proteins and bioactive peptides in inflammatory bowel disease. <i>Trends in Food Science and Technology</i> , <b>2019</b> , 88, 194-206	15.3	31
141	A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 6927-34	5.6	31
140	Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 1037-1048	1.5	30
139	Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 554-8	4.5	30
138	Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , <b>2016</b> , 39, 508-15	0.9	30
137	Endoscopist characteristics that influence the quality of colonoscopy. <i>Endoscopy</i> , <b>2016</b> , 48, 241-7	3.4	29

136	Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 1529-38	1.5	28
135	The Innate Immune System in the Gastrointestinal Tract: Role of Intraepithelial Lymphocytes and Lamina Propria Innate Lymphoid Cells in Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 1649-1659	4.5	28
134	Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment. <i>Journal of Crohn's and Colitis</i> , <b>2016</b> , 10, 1186-93	1.5	26
133	Human Intestinal Dendritic Cells in Inflammatory Bowel Diseases. <i>Molecular Nutrition and Food Research</i> , <b>2018</b> , 62, e1700931	5.9	24
132	Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 183-90	1.5	24
131	Health care costs of complex perianal fistula in Crohn's disease. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 3400-6	4	24
130	Incidence, management, and course of cancer in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 326-33	1.5	23
129	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 205-221	0.9	23
128	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 514-529	0.9	23
127	'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 127-137	1.5	23
126	Vaccination strategies in patients with IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2013</b> , 10, 277-85	24.2	22
125	Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , <b>2011</b> , 34, 385-92	0.9	22
124	Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience. <i>Gastroenterología Y Hepatología</i> , <b>2011</b> , 34, 443-8	0.9	22
123	Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study. <i>Journal of Crohn's and Colitis</i> , <b>2010</b> , 4, 629-36	1.5	22
122	Effectiveness of infliximab after adalimumab failure in Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 5219-24	5.6	22
121	Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1605-1613	4.5	21
120	Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 3075-84	4	21
119	Endothelial MT1-MMP targeting limits intussusceptive angiogenesis and colitis via TSP1/nitric oxide axis. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e10862	12	21

118	Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , <b>2013</b> , 7, e569-79	1.5	21
117	Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. <i>Journal of Crohn's and Colitis</i> , <b>2011</b> , 5, 397-401	1.5	21
116	Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease. <i>Microorganisms</i> , <b>2021</b> , 9,	4.9	21
115	Mechanisms of angiogenesis in chronic inflammatory liver disease. <i>Annals of Hepatology</i> , <b>2007</b> , 6, 208-133.1	3.1	21
114	Acute severe ulcerative colitis: State of the art treatment. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2018</b> , 32-33, 59-69	2.5	20
113	Ratio of Circulating Estrogen Receptors Beta and Alpha (ER $\beta$ /ER $\alpha$ ) Indicates Endoscopic Activity in Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 2744-2754	4	20
112	Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 374-384	1.5	20
111	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 606-616	4.5	19
110	Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 353-359	3.3	19
109	Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 493-8	5.6	19
108	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> ,	1.5	19
107	Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?. <i>Scandinavian Journal of Gastroenterology</i> , <b>2015</b> , 50, 379-86	2.4	18
106	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease. <i>Gastroenterología Y Hepatología</i> , <b>2017</b> , 40, 472-483	0.9	18
105	Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease. <i>Current Drug Metabolism</i> , <b>2011</b> , 12, 594-8	3.5	18
104	Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 419-428	6.1	18
103	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	17
102	Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2016</b> , 10, 657-62	1.5	17
101	Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 389-405	0.9	17



100	Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2012</b> , 6, 1034-7	1.5	16
99	New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 631-40	2.6	16
98	Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1135-1143	0.7	15
97	Immunomodulatory Effect of Gut Microbiota-Derived Bioactive Peptides on Human Immune System from Healthy Controls and Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	15
96	The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 695-702	4.5	15
95	Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 846-854	4	15
94	High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. <i>Blood Transfusion</i> , <b>2016</b> , 14, 199-205	3.6	14
93	Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 792-800	1.5	13
92	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients. <i>Gastroenterología y Hepatología</i> , <b>2018</b> , 41, 118-127	0.9	13
91	Maintenance therapy options for ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 1339-42		13
90	Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 35-42	1.5	13
89	Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. <i>Drugs</i> , <b>2020</b> , 80, 1085-1100	12.1	12
88	Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 1270-1279	1.5	12
87	The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	12
86	How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 733-7	3.3	11
85	Influenza A (H1N1)v infection in patients with inflammatory bowel disease: a case series. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 499-500	6.1	11
84	Clinical Course of Bone Metabolism Disorders in Patients with Inflammatory Bowel Disease: A 5-Year Prospective Study. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 1929-36	4.5	11
83	Importance of endoscopist quality metrics for findings at surveillance colonoscopy: The detection-surveillance paradox. <i>United European Gastroenterology Journal</i> , <b>2018</b> , 6, 622-629	5.3	11

82	How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?. <i>Expert Opinion on Drug Safety</i> , <b>2014</b> , 13, 1749-62	4.1	10
81	Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 2260-2	5.6	10
80	Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2012</b> , 6, 950-3	1.5	10
79	Epidemiology: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819847034	4.7	9
78	Effectiveness of anti-TNF drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNF agent. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 613-9	3.3	9
77	Effect of Chondroitin Sulphate on Pro-Inflammatory Mediators and Disease Activity in Patients with Inflammatory Bowel Disease. <i>Digestion</i> , <b>2015</b> , 92, 203-10	3.6	9
76	Successful use of infliximab for perianal Crohn's disease in pregnancy. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 868-9	4.5	9
75	Azathioprine plus ribavirin treatment and pancytopenia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 962-3	6.1	9
74	Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. <i>Biochemical Pharmacology</i> , <b>2016</b> , 122, 33-41	6	9
73	Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 152-157	2.4	9
72	Ustekinumab to treat Crohn's disease. <i>Gastroenterología Y Hepatología</i> , <b>2017</b> , 40, 688-698	0.9	8
71	Validation of a genotyping method for analysis of TPMT polymorphisms. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 878-84	3.5	8
70	Peptides encrypted in the human intestinal microbial-exoproteome as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract. <i>Journal of Functional Foods</i> , <b>2019</b> , 52, 459-468	5.1	8
69	Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 155-168	1.8	7
68	Computed tomography colonography compared with conventional colonoscopy for the detection of colorectal polyps. <i>Gastroenterología Y Hepatología</i> , <b>2007</b> , 30, 375-80	0.9	7
67	Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 766	5.3	6
66	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. <i>Gastroenterología Y Hepatología</i> , <b>2019</b> , 42, 568-578	0.9	5
65	Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1802-1811	0.7	5



64	Sa1903 Effectiveness and Safety of Ustekinumab as Rescue Therapy in Multi-Drug Resistant Crohn's Disease. <i>Gastroenterology</i> , <b>2012</b> , 142, S-355	13.3	4
63	Prospective evaluation of a clinical guideline recommending early patients discharge in bleeding peptic ulcer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2010</b> , 25, 1525-9	4	4
62	Epidemiological Study of Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2011</b> , 140, S-736	13.3	4
61	Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
60	Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2020</b> , 43, 155-168	0.1	3
59	Tu1990 Correlation Between Anti-TNF Serum Levels and Mucosal Healing (MH) in Inflammatory Bowel Disease (IBD) Patient. <i>Gastroenterology</i> , <b>2016</b> , 150, S999	13.3	3
58	Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease. <i>Gastroenterología Y Hepatología</i> , <b>2016</b> , 39, 255-60	0.9	3
57	Overall Incidence of Hepatosplenic T Cell Lymphoma in Patients With Inflammatory Bowel Disease on Thiopurines: A Meta-Analysis of Three Population Based Studies. <i>Gastroenterology</i> , <b>2011</b> , 140, S-775	13.3	3
56	Comparative Study to Evaluate the Effectiveness of Two Different Vaccination Protocols Against Hepatitis B Virus (HBV) in Inflammatory Bowel Disease (IBD) Patients. <i>Gastroenterology</i> , <b>2011</b> , 140, S-587-588 <sup>3</sup>	13.3	3
55	Tips and guidelines for being a successful researcher. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 540-550	0.9	3
54	Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1846-1851	1.5	3
53	Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
52	Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 273-283	0.9	3
51	Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 144, 112239	7.5	3
50	Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: the Practicrohn study. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 807-813	4.2	2
49	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 588-596	2.2	2
48	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2018</b> , 41, 205-221	0.1	2
47	Tu1925 Real-Life Experience With Golimumab in Ulcerative Colitis Patients According to Prior Anti-TNF Use. <i>Gastroenterology</i> , <b>2016</b> , 150, S979	13.3	2

46	Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature. <i>Journal of Crohn's and Colitis</i> , <b>2013</b> , 7, e61-5	1.5	2
45	Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
44	Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease. <i>Current Drug Metabolism</i> , <b>2014</b> , 15, 875-81	3.5	2
43	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> ,	1.5	2
42	Demographic Difference of Hepatosplenic T-Cell Lymphoma (HSTCL) Versus Non-HSTCL Lymphoma in Patients with IBD Receiving Thiopurines: A Population Cohort Analysis. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, S632	0.7	2
41	Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal Tract. <i>Molecular Nutrition and Food Research</i> , <b>2021</b> , 65, e2001034	5.9	2
40	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
39	The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211018097	4.7	2
38	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 649-658	0.9	1
37	Manifestaciones extraintestinales en la enfermedad inflamatoria intestinal. <i>Medicine</i> , <b>2016</b> , 12, 242-248	0.1	1
36	Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 940-1	6.1	1
35	Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 120-1	6.1	1
34	Letter: dry blood spots for anti-TNF treatment monitoring in IBD--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 1025-6	6.1	1
33	Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2011</b> , 36, 695-703	2.2	1
32	How to prepare a research proposal in the health sciences?. <i>Gastroenterología Y Hepatología</i> , <b>2021</b> , 44, 730-740	0.9	1
31	Diagnosis and Outcome of Oesophageal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 624-629	2.5	1
30	Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 1277-1288	6.1	1
29	Profiling of Human Circulating Dendritic Cells and Monocyte Subsets Discriminates Between Type and Mucosal Status in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 268-274	4.5	1

28	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2018</b> , 41, 514-529	0.1	1
27	Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2018</b> , 41, 389-405	0.1	1
26	Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
25	Challenges of independent clinical research. <i>Gastroenterología Y Hepatología</i> , <b>2021</b> , 44, 599-610	0.9	1
24	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> ,	1.5	1
23	Letter: measurement of anti-TNF-levels and antibodies against the drug. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 163-4	6.1	0
22	Survey of adherence to treatment in inflammatory bowel disease. ENADEII study. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 285-292	0.9	0
21	Quality of care through the eyes of the patient in a Spanish inflammatory bowel disease unit. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2020</b> , 112, 688-693	0.9	0
20	Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 806-811	2.4	0
19	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial.. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819874202	4.7	0
18	Tissue Proteomic Approaches to Understand the Pathogenesis of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1184-1200	4.5	0
17	Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819867848	4.7	
16	Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 1302-3	6.1	
15	Errors in the care of inflammatory bowel disease patients: Errata Study. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2020</b> , 43, 233-239	0.1	
14	Actualización del diagnóstico y tratamiento de la enfermedad de Crohn. <i>Medicine</i> , <b>2016</b> , 12, 217-226	0.1	
13	Protocolo de diagnóstico y tratamiento de la colitis ulcerosa grave corticorrefractaria. <i>Medicine</i> , <b>2016</b> , 12, 260-262	0.1	
12	Reply to Dr. Katsanos et al.'s letter. <i>Journal of Crohn's and Colitis</i> , <b>2013</b> , 7, e23-4	1.5	
11	Ustekinumab to treat Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2017</b> , 40, 688-698.	0.1	

10	Letter: mucosal PCR for cytomegalovirus in refractory ulcerative colitis Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 812-812	6.1
9	Response to Tung et al. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 621-2	0.7
8	Antimetabolite Therapy in Ulcerative Colitis: Azathioprine, 6-Mercaptopurine, and Methotrexate <b>2014</b> , 135-143	
7	Errors in the care of inflammatory bowel disease patients: "Errata" Study. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 233-239	0.9
6	Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 1020	6.1
5	Treatment of inflammatory bowel disease: what's new in Digestive Disease Week 2016. <i>Gastroenterología Y Hepatología</i> , <b>2016</b> , 39 Suppl 1, 20-28	0.9
4	Outcome after a dose De-intensification strategy with anti-TNF drugs in patients with Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2016</b> , 39, 255-260	0.1
3	New molecules in the treatment of inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2016</b> , 39, 411-423	0.1
2	Response to the Letter to the Editor: "Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease". <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, e6	4.5
1	Pregnancy and Inflammatory Bowel Disease: A Long Way to Go. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1903-1904	0.7